About M Ventures
M Ventures is a venture capital firm founded in 2009. It is primarily based out of Amsterdam, Netherlands. As of Jun 2026, M Ventures is an active investor, having invested in 113 companies, with 5 new investments in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Seed round of Trimtech Therapeutics Overall, M Ventures portfolio has seen 5 IPOs and 17 acquisitions including key companies like Celestial AI, Xilio Therapeutics and Progyny. A lot of funds co-invest with M Ventures, with names like Foothill Ventures sharing a substantial percentage of its portfolio. M Ventures has team of 17 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Seed & 5 more
Portfolio IPOs
Portfolio Acquisitions
Deals in last 12 months
M Ventures' List of Top Investments
M Ventures has a portfolio of 113 companies. Their most notable investments are in Altoida and Indi Molecular.Their portfolio spans across United States, United Kingdom, Switzerland and 10 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 15 other sectors, across stages such as Series A, Seed and 5 more. Here is the list of top investments by M Ventures:
1. Celestial AI
Developer of optical interconnect technology for artificial intelligence infrastructure systems. The company’s technology aims to improve artificial intelligence system performance through optical interconnectivity. It focuses on enabling efficient scaling of artificial intelligence to advance progress in various fields. The company’s platform is designed for integration into next-generation artificial intelligence systems.
Key facts about Celestial AI
- Founded Year: 2020
- Location: Santa Clara (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $589M
- Employee Count: 68 as on May 31, 2026
- Investors: Fidelity Investments, Samsung Catalyst Fund and 21 Others
- Latest Funding Round: Series C, Feb 25, 2025, $*****
- Highlight: Acquired
Developer of immunotherapies for the treatment of cancer. The company is developing its proprietary technology to create an IO therapy that is activated selectively within the tumor. The product XTX201 (IL-2) induces immune activity in tumors without the toxicity seen with non-selective IL-2s, XTX101, XTX301, and XTX401 demonstrates antitumor activity.
Key facts about Xilio Therapeutics
- Founded Year: 2016
- Location: Waltham (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $233M
- Employee Count: 94 as on May 31, 2026
- Investors: Bain Capital Life Sciences, Deerfield and 16 Others
- Latest Funding Round: Post IPO, Feb 12, 2025, $*****
- Highlight: Public
3. Wiliot
Provider of a platform delivering real-time supply chain intelligence solutions. The platform offers scan-free solutions, reducing errors and waste across enterprises. It connects physical items to the cloud using battery-free sensors and network infrastructure. The platform transforms raw data into actionable insights for efficient operations. It provides inventory intelligence, workflow optimization, and condition monitoring.
Key facts about Wiliot
- Founded Year: 2017
- Location: Caesarea (Israel)
- Stage: Series C
- Total Funding till date: $364M
- Employee Count: 263 as on May 31, 2026
- Investors: Cerca Partners, Vintage Investment Partners and 21 Others
- Latest Funding Round: Series C, Apr 27, 2026, $*****
- Highlight: Editors' Pick
4. Progyny
Provider of women’s health, fertility, family building benefits, and insurance. The company offers end-to-end benefits designed to be flexible and equitable, allowing members access to care and support. Programs include preconception, fertility, adoption, surrogacy, pregnancy, postpartum, return-to-work, parent and child well-being, menopause, and midlife support. The company provides access to a network of women’s health providers.
Key facts about Progyny
- Founded Year: 2008
- Location: New York City (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $67.4M
- Employee Count: 920 as on May 31, 2026
- Investors: HTIF, Union Grove Venture Partners and 6 Others
- Latest Funding Round: Series B, May 02, 2017, $*****
- Highlight: Public
Galecto Biotech is a clinical-stage biopharma developing galectin modulators for idiopathic pulmonary fibrosis and other severe diseases, including fibrosis and cancer. It has developed ultra-potent galectin-3 inhibitors that specifically block the binding of galectin-3 to carbohydrate structures. The lead candidate, TD-139, completed Phase Ib/IIa trials. TD139 is a highly potent, specific inhibitor of the galactoside binding pocket of galectin-3. TD139 was initially developed by a team.
Key facts about Galecto Biotech
- Founded Year: 2010
- Location: Copenhagen (Denmark)
- Stage: Public
- Total Funding till date: $160M
- Investors: HBM Healthcare Investments, Janus Henderson Investors and 21 Others
- Latest Funding Round: Series D, Sep 25, 2020, $*****
- Highlight: Public
M Ventures' Year-on-Year Investment Trends
M Ventures has invested in 113 companies over the last 16 years, with an average of 8 new investments annually in the last 10 years. In 2025, it made 17 investments, while as of Jun 2026, it has made 4 investments in this year. Its most recent first time investment was in VIZGEN and most recent follow-on round was in Trimtech Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 4 | 4 |
2025 | 9 | 8 | 17 |
2024 | 11 | 10 | 21 |
2023 | 11 | 3 | 14 |
2022 | 5 | 6 | 11 |
2021 | 6 | 9 | 15 |
2020 | 9 | 5 | 14 |
2019 | 9 | 7 | 16 |
2018 | 5 | 2 | 7 |
2017 | 9 | 3 | 12 |
M Ventures' Investments by Stage
M Ventures is primarily an Early Stage Investor investor majorly investing in Series A (52) rounds where average round size is $893M, Seed (24) rounds where average round size is $223M and Series B (15) rounds where average round size is $514M.Stage of entry | No. of Investments |
|---|---|
Series A | 52 |
Seed | 24 |
Series B | 15 |
Post IPO | 1 |
Series C | 1 |
Others | 2 |
Note: We have considered here, only first round of investments
M Ventures' Investments by Sector
M Ventures has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, Semiconductors and HealthTech. Notably, it has invested in 101 Tech companies, 86 Enterprise (B2B) companies, 35 Software companies and at least 25 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 59 |
High Tech | 31 |
Enterprise Applications | 17 |
Semiconductors | 15 |
HealthTech | 13 |
Others | 44 |
Note: We have considered here, only first round of investments
M Ventures' Investments by Geography
M Ventures has made most investments in United States (43), followed by United Kingdom where it has made 14 investments.Country | No. of Investments |
|---|---|
United States | 43 |
United Kingdom | 14 |
Switzerland | 9 |
Germany | 7 |
Israel | 7 |
Others | 15 |
Note: We have considered here, only first round of investments
M Ventures' recent investments
M Ventures has made 4 investments in 2026 so far. Trimtech Therapeutics and Future Fertility are the latest among them.Here are the most recent investments by M Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 23, 2026 | United Kingdom | Seed | 9357 | ||
Apr 23, 2026 | Canada | Series A | 5818 | ||
Apr 16, 2026 | United Kingdom | Series C | 8550 | [+4] | |
Apr 15, 2026 | United Kingdom | Series B | 2841 | ||
Dec 29, 2025 | United States | Series E | 5643 |
IPOs and Publicly Listed companies in M Ventures' Portfolio
5 of M Ventures' portfolio companies have become public. Xilio Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Oct 2021 at marketcap of $427M and Galecto Biotech got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $369M.Here are M Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 22, 2021 | Mar 02, 2020 | Series B | 3913 | |
Oct 29, 2020 | May 02, 2012 | Seed | 4680 | |
Oct 25, 2019 | Apr 21, 2015 | Series A | 3382 | |
Jan 26, 2017 | - | - | 6914 | |
Jun 20, 2014 | Nov 10, 2015 | Post IPO | 2391 |
Acquired companies in M Ventures' Portfolio
17 companies from M Ventures' portfolio have been acquired. The most recent acquisition was Lumiode in Dec 2025 by PlayNitride for $*****.Here are M Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 16, 2025 | - | - | 5172 | |
Dec 02, 2025 | Dec 15, 2021 | Series A | 6857 | |
Dec 16, 2024 | May 12, 2022 | Series A | 5314 | |
May 29, 2024 | Jul 20, 2016 | Series B | 7645 | |
Jan 08, 2024 | - | - | 1574 |
Team profile of M Ventures
M Ventures has a team of 17 members including 2 Partners, 1 Venture Partner and 11 Principals located in Germany, Netherlands and 3 more locations. M Ventures' team does not sit on the board of any company as of now.Here is a list of top team members in M Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Amsterdam | - | ||
Partner | Germany | - | ||
Venture Partner | Zurich | - | - | |
Principal | Frankfurt Am Main | - | ||
Principal | Boston | - | ||
Principal | Darmstadt | - | ||
Principal | Darmstadt | - | ||
Principal | United Kingdom | - | ||
Principal | Amsterdam | - | ||
Principal | Cambridge | - | ||
Principal | - | - |
Co-investors of M Ventures
Over the past 16 years, 692 investors have co-invested in M Ventures's portfolio companies. This includes funds and angels.
- Invested before M Ventures: SV Health Investors, Novo Holdings and 175 others have invested in rounds before M Ventures. There are 4 companies where SV Health Investors has invested before M Ventures and 4 companies where Novo Holdings has invested before M Ventures.
- Top Co-investors of M Ventures: 221 investors entered a company along with M Ventures. These include investors like Foothill Ventures (5 companies).
- Invested after M Ventures: A total of 294 investors have invested in M Ventures's portfolio after their investments. Top Investors include EQT (5 companies), Europa (4 companies) and EIC Fund (4 companies).
Recent News related to M Ventures
•
News Storm clinches $56m in Series C for Phase II on lead sarcoma drugclinicaltrialsarena.com•Apr 16, 2026•STORM Therapeutics, Pfizer, M Ventures, FTI and 3 others
•
Lightcast Raises $27 Million to Push Functional Single-Cell Analysis Toward the Lab BenchTechnologies.org•Apr 15, 2026•Lightcast, Arch Venture Partners, ND Capital, OMX Ventures and 3 others
•
Intellend raises $1.2 Mn in seed round led by Incubate Fund AsiaEntrackr•Jan 20, 2026•Atrium, Intellend Technologies Advisors, MVP, M Ventures and 2 others
•
•
Lucidean Pulls In $18M Seed RoundMassinvestor•Dec 24, 2025•Foothill Ventures, Koch Disruptive Technologies, Lucidean, Cerberus Ventures and 3 others
•
NovoLINC Secures Funding to Advance Thermal Tech for AI ChipsPR Newswire•Dec 18, 2025•Foothill Ventures, Carnegie Mellon University, Fathom Fund, Hitachi Ventures and 3 others
•
FoRx Therapeutics Raises USD50M in Series A FinancingFinSMEs•Dec 18, 2025•Pfizer, Novartis Venture Fund, EQT, M Ventures and 1 other
•
DISCO Pharmaceuticals Appoints Mark Manfredi as CEO & Closes €36M Seed FinancingBenzinga•Dec 11, 2025•DISCO Pharmaceuticals, Ackermans, NRW.Bank, Panakes Partners and 4 others
•
Artios Pushes Cancer Pipeline Forward With $115M Series DBioSpace•Nov 17, 2025•Pelage Pharmaceuticals, Artios, Kriya Therapeutics, VeraDermics and 18 others
•
Germany’s FMC secures €100M to lessen reliance on US & Asian memory suppliersEU-Startups•Nov 13, 2025•DeepTech & Climate Fonds, HV Capital, Ferroelectric Memory Company, HTGF and 12 others
